Anti-CTLA-4 plus conventional therapy was associated with significantly increased odds of hepatitis compared with conventional therapy (OR 200.17, 95% CrI 6.61 to 297,489), anti-PD-1/PD-L1 plus conventional therapy (OR 48.32, 95% CrI 1.34 to 71,719), and anti-PD-1 or anti-PD-L1 (OR 36.83, 95% CrI 1.05 to 56,704.7). The gene discussed is CD274; the disease is hepatitis A virus infection.